SCEMBLIX is indicated for the treatment of adult patients with:• Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs).• Ph+ CML in CP with the T315I mutation